Cipla launches lung-disease generic Pirfenidone

21 Oct 2010 Evaluate

Cipla has launched the generic version of Pirfenidone, used to treat Idiopathic Pulmonary Fibrosis, a progressive lung disease. The launch makes India only the second market to have this drug, besides Japan. The drug that addresses an “unmet medical need,” is yet to get approvals in other markets where it is an experimental drug.

 

In India, the medicine is priced at Rs 28 for a tablet, significantly less than in Japan, and the dosage for this condition is usually about two tablets taken three times a day. This works out to about Rs 5,000 a month for a person taking the medicine. Branded Pirfenex, the medicine will be made at Cipla's plant in Himachal Pradesh.

 

The incidence of the illness in India is not known, but is expected to be higher than the prevalence in the US — about 30,000 new cases per year, The disease causes the lung to be replaced by scar tissue – though the cause of the illness is still not clear, varying from environmental illness to smoking, he said. But once it is diagnosed, about 50 per cent die in three years.

crackcrack

Cipla Share Price

1421.00 81.55 (6.09%)
13-May-2024 15:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1530.00
Dr. Reddys Lab 5913.95
Cipla 1421.00
Zydus Lifesciences 993.40
Lupin 1684.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.